December 15, 2022 8:00 AM - 9:00 AM ET
Overview
CLL is the most prevalent leukemia in adults, and although it is typically a slow progressing disease, relapsed/refractory disease and the development of resistance to standard therapies are common. Although CLL has traditionally been treated with chemotherapeutic strategies, such as FCR, many patients do not have the performance status to tolerate chemotherapeutic approaches. BTK inhibitors have become an integral part of CLL treatment regimens in both frontline and relapsed/refractory disease settings, and recent advances with these novel agents have improved patient outcomes and safety. Practitioners face a continuous challenge to stay current with advances and need both access to emerging clinical data and expert guidance on how to incorporate these data into patient care.
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL is a CE-certified live webcast to be held on Thursday, December 15, 2022. In this educational program, 2 expert medical oncologists will review and discuss recently presented abstracts from the annual hematology meeting. The faculty will share their own clinical pearls and practice preferences in applying the evidence from recent clinical trials assessing novel agents and combinations in both the frontline and relapsed/refractory settings.
Target audience
This educational activity is directed toward hematologists, oncologists, NPs, and nurses interested in the treatment of CLL.
Learning objectives
Upon completion of this activity, participants will be able to:
- Determine how risk stratification and MRD assessment has been incorporated as part of recent trial designs conducted in CLL settings
- Explain key inclusion/exclusion criteria as well as efficacy and safety findings from recent trials that evaluated evolving approaches to manage CLL
- Assess strategies for practitioners to proactively identify and manage treatment-related toxicities that occurred in trials conducted among patients with CLL
- Describe the clinical implications of recent evidence from CLL trials in the context of evolving care paradigms in the field
Benefits of Attending
- Receive the latest information on recent clinical data in both frontline and relapsed/refractory settings of CLL
- Learn about novel BTK inhibitors in development for relapsed/refractory CLL
- Hear experts discuss how to apply the evidence on new CLL data in the clinic
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL 8:00 am ET Live Webcast |
||
Time |
||
8:00 AM |
Welcome and Introductions |
Catherine C. Coombs, MD |
8:05 AM |
Review of Abstract 344: Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease Christine E. Ryan, MD |
Catherine C. Coombs, MD |
8:15 AM |
Review of Abstract 347: Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study William G. Wierda, MD, PhD and Review of Abstract 961: Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study Anthony R. Mato, MD, MSCE |
Anthony R. Mato, MD, MSCE |
8:25 AM |
Review of Abstract LBA-6: Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study Jennifer R. Brown, MD, PhD |
Catherine C. Coombs, MD |
8:35 AM |
Review of Abstract 965: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies Anthony R. Mato, MD, MSCE |
Anthony R. Mato, MD, MSCE |
8:45 AM |
Panel Discussion: Applying the Latest Data and Ongoing Trials to the Care of Your Patients with CLL |
Catherine C. Coombs, MD Anthony R. Mato, MD, MSCE |
8:55 AM |
Summary and Conclusions |
Anthony R. Mato, MD, MSCE |
9:00 AM |
Adjourn |
|
Anthony R. Mato, MD, MSCE
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, NY
Catherine C. Coombs, MD, MS
Associate Clinical Professor
University of California, Irvine
Department of Medicine
Division of Hematology and Oncology
Orange, CA
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.